

INDEX

- Aboriginal participants, 69–71
- accountability, 93–4
- action research, 26
- adverse drug reactions (ADRs), 37
- application of values and principles, 13
- appointment of HREC members, 81
- approval withdrawn after review, 92
- ARC Act, 5
- archival research, 26
- ART Guidelines, 47
- assessment of risk, 15–16
- Australian code for the responsible conduct of research*, 4, 93
- Australian Health Ethics Committee, 4
- Australian Research Council Act 2001*, 5
- Australian Vice-Chancellors' Committee (AVCC), 5
- autonomy, value of, 11
-
- banked data, 29–30
- beneficence, 13
- central to ethical conduct, 11
 - cognitively impaired participants, 66
 - dependent or unequal relationships, 60
 - genetic research, 43
 - illegal activities, participants involved in, 68
 - Indigenous participants, 70
 - medically dependent participants, 62
 - overseas research, 74
 - paediatric research, 56
 - qualitative methods, 27–8
 - stem cell research, 49
- benefits of research, 15–18
- best interests of the child, 57
- blood relatives
- ethical issues for, 41–4
 - standing parental consent, 57
- British Research Assessment Exercise, 7
-
- cadaveric tissue, 40
- cessation of research, 91–2
- children, 55–7, *see also* foetal involvement in research
- neonates, 54, 62
- clinical research, 33–4
- coercion of consent, 20
- cognitively impaired participants, 65–6
- commercial tissue use, 40
- communication with review bodies, 84–5
- community involvement in genetic research, 44–5
- complaint handling, 93
- composition of HRECs, 80–1
- confidentiality in genetic research, 45
- conflicts of interest, 89–90
- conscientious objection to stem cell research, 49
- consent
- banked data, 31
 - qualifying or waiving, 23–4
 - qualitative methods, 28
 - requirements for, 19–21
 - standing parental consent, 57
 - tissue use, 40
- cross-border research, 73–5
- custodians of data, 30–1
-

- data
- in databanks, 29–31
 - qualitative collection, 25–6
 - usage of, 21, 30
- Data and Safety Monitoring Boards, 37
- databanks, 29–31
- de-identified data, 29
- decision making by review bodies, 84–5
- declining consent, 21
- dependent relationships, 59–60
- devaluation of personal worth, 16
- disclosure
- limiting, 23–4
 - that research has ceased, 91–2
- discomfort from research, 16
- discontinuance of trials, 37–8
- disease predispositions, 41
- distributive justice, 11, *see also* justice
- documentation by review bodies, 85
- DSMBs, 37
- duplication, minimising, 87
-
- E-groups, 26
- economic harms, 16
- embryos, 39, 47, 52, *see also* foetal involvement in research
- emergency care research, 62
- establishment of HRECs, 80
- ethical conduct
- background to, 3–4
 - values and principles, 11–13
- Ethical guidelines on the use of assisted reproductive technology in clinical practice and research*, 47
- ethical review
- approval withdrawn after, 92
 - governance and, 77–96
 - when needed?, 8
- exempted research, 79
- experts at review body meetings, 84
- extended consent, 21
-
- families, *see* blood relatives
- focus groups, 26
- foetal involvement in research, 51–4
- future use of data or tissue, 21
-
- gamete research, 39
- gauging risk, 15–16
- genetic research, 41–5
- genomes, 41
- glossary, 99–102
- governance and ethical review, 77–96
-
- handling complaints, 93
- Helsinki Declaration, 3
- human genetics, 41–5
- human research, 3, 8
- Human Research Ethics Committees, 1, 79–85
- human stem cells, 47–9
- human tissue, 39–40
-
- illegal activities, participants involved in, 67–8
- imported stem cells, 49
- imported tissue, 39–40
- inconvenience from research, 16
- Indigenous participants, 69–71
- individually identifiable data, 29
- infants, *see* children
- information about tissue use, 40
- innovations in clinical practice, 33
- institutional policy, 39
- institutional responsibilities, 77–82
- insurance requirements, 38

integrity in research, 12–13, *see also* merit and integrity

intellectually disabled participants, 65–6

intensive care research, 62

international research, 73–5

interventions, 33–8

interviews, 26

justice, 12

central to ethical conduct, 11

clinical trials, 35

cognitively impaired participants, 65–6

dependent or unequal relationships, 59–60

genetic research, 43

illegal activities, participants involved in, 68

Indigenous participants, 70

medically dependent participants, 61–2

overseas research, 74

paediatric research, 56

qualitative methods, 27

stem cell research, 48

key informant interviews, 26

legal issues, 8–9

harm from research, 16

protection for ethical review team, 78

stem cell research, 47

life story, 26

limited disclosure, 23–4

limits of National Statement, 7–9

low risk research, 8, 16, 79

medical care, patients dependent on, 61–3

meetings of HRECs, 85–6

mentally ill participants, 65–6

merit and integrity, 12–13

clinical trials, 34–5

cognitively impaired participants, 65

databanks, 30

dependent or unequal relationships, 59

genetic research, 42

illegal activities, participants involved in, 67

Indigenous participants, 70

medically dependent participants, 61

overseas research, 73

paediatric research, 55–6

qualitative methods, 26

stem cell research, 48

minimising duplication, 87

minimising risk, 17

monitoring

approved research, 91–2

clinical trials, 36–7

National Health and Medical Research Council Act 1992, 4

National Statement, 7–9

negligible risk research, 16

neonatal intensive care research, 62

NHMRC Act, 4

non-identifiable data, 29

non-participants, risks to, 16, *see also* third parties

Nuremberg Code, 3

observational studies, 26

on-line research, 26

oral history, 26

overseas research, 73–5

oversight of research, 78–9

- paediatric research, 55–7
- participants in research
- defined, 8
 - ethical issues for, 51–75
 - interests of, 84
 - payment of, 20
- patients dependent on medical care, 61–3
- payment for participants, 20
- Phase I, II, III and IV trials, 33–4
- physical harm, 16
- placebos, 35
- preamble, 3–5
- predispositions to disease, 41
- pregnant women, 51–4
- pressure to consent, 20
- primordial germ cells, 47
- principles of ethical conduct, 11–13
- process report, 97–8
- psychological harm, 16
- purpose of National Statement, 7–9
-
- qualifying consent, 23–4
- qualitative methods, 25–8
-
- randomised clinical trials, 33–4
- re-identifiable data, 29
- record-keeping, 36, 85
- reimbursement of participants, 20
- relatives, *see* blood relatives; third parties
- renegotiating consent, 20
- requirements for consent, 19
- research
- defined, 7–8
 - governance and ethical review, 77–96
 - harm from, 16
 - merit and integrity, 12–13
 - researcher responsibilities, 83
 - risks and benefits, 15–18
- Research Code, 4, 93
- research governance, 4
- Research Involving Human Embryos Act 2002*, 47
- respect, 11–13
- clinical trials, 36
 - cognitively impaired participants, 66
 - dependent or unequal relationships, 60
 - illegal activities, participants involved in, 68
 - Indigenous participants, 70–1
 - medically dependent participants, 62
 - overseas research, 75
 - paediatric research, 56–7
 - qualitative methods, 28
 - stem cell research, 49
- review body procedures, 83
- rigour of research, 27
- RIHE Act, 47
- risk management, 3, 15–18, 35
-
- sample informant interviews, 26
- sampling strategy, 27
- saturation, 27
- scope of National Statement, 7–9
- semi-structured interviews, 26
- serious unexpected serious adverse reactions, 37
- social harms, 16
- somatic stem cells, 47
- specific consent, 21
- standing parental consent, 57
- stem cell research, 47–9
- structured interviews, 26
- SUSARs, 37
- suspension of research, 91–2

terminal care research, 62
termination of pregnancy, 53–4
therapies, 33–8
third parties, 16, 20–1, *see also* blood relatives;
non-participants, risks to
tissue
 foetal, 52–4
 future use of, 21
 samples, 39–40
 tissue banks, 29
Torres Strait Islander participants, 69–71

unconscious people, research with, 62
unequal relationships, 59–60
unspecified consent, 21
unstructured interviews, 26
use of National Statement, 7
user guide, 1–2

Values and Ethics guidelines, 69
values of ethical conduct, 11–13

waiving consent, 23–4
withdrawal
 of approval, 92
 of consent, 21

young people, 55–7